![]() ![]() Michael Bogan, president of ICQ Consultants, commented, “We are very excited to join Yokogawa in this strategic partnership agreement to help facilitate the support of their bioreactor systems and related products throughout the United States. The BR1000 automates lab-scale mammalian cell culture with highly accurate real-time monitoring and advanced process control. Through in-line sensing and model predictive control software, and automated feeding, a stable concentration of glucose in bioreactors can be achieved. For complete automation of the fed-batch mammalian cell culture process, the control of glucose - a key nutrient source - is critical. The automation of manual processes is a rapidly advancing trend in the biopharmaceutical industry. ![]() The first portfolio product, the Advanced Control Bioreactor System BR1000 was recently released on January 8, offering significant performance advantages over existing methods for biologics development. As part of this partnership agreement, Yokogawa will leverage ICQ Consultants’ engineering and laboratory expertise in the biopharmaceutical segment to deploy its new bioprocess technologies in the United States. Since 2007, ICQ Consultants has played an important role in the commissioning and qualification of manufacturing plants in the major life sciences hubs in the United States, including some of the world’s largest biomanufacturing facilities. The next issue of Financial Post Top Stories will soon be in your inbox. If you don't see it, please check your junk folder. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |